Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in Richmond, Virginia.
Industry, Sector and Symbol
Industry Tobacco products
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-17-5321-7800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.01 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/1/2019 (Estimated)
OptionableNot Optionable
INDIVIOR PLC/S (OTCMKTS:INVVY) Frequently Asked Questions
What is INDIVIOR PLC/S's stock symbol?
INDIVIOR PLC/S trades on the OTCMKTS under the ticker symbol "INVVY."
How were INDIVIOR PLC/S's earnings last quarter?
INDIVIOR PLC/S (OTCMKTS:INVVY) announced its quarterly earnings data on Thursday, February, 14th. The company reported $0.45 earnings per share for the quarter. The firm earned $236 million during the quarter. INDIVIOR PLC/S had a net margin of 27.49% and a return on equity of 1,153.52%. View INDIVIOR PLC/S's Earnings History.
When is INDIVIOR PLC/S's next earnings date?
What is the consensus analysts' recommendation for INDIVIOR PLC/S?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INDIVIOR PLC/S in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for INDIVIOR PLC/S.
Has INDIVIOR PLC/S been receiving favorable news coverage?
News coverage about INVVY stock has been trending negative on Thursday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. INDIVIOR PLC/S earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are some of INDIVIOR PLC/S's key competitors?
What other stocks do shareholders of INDIVIOR PLC/S own?
Who are INDIVIOR PLC/S's key executives?
INDIVIOR PLC/S's management team includes the folowing people:
- Mr. Shaun Thaxter, CEO & Exec. Director
- Mr. Mark Crossley, CFO & Exec. Director
- Dr. Christian Heidbreder, Chief Scientific Officer
- Mr. Ingo Elfering, Chief Information & Innovation Officer
- Mr. Jason Thompson, VP of Investor Relations
How do I buy shares of INDIVIOR PLC/S?
Shares of INVVY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is INDIVIOR PLC/S's stock price today?
One share of INVVY stock can currently be purchased for approximately $6.91.
How big of a company is INDIVIOR PLC/S?
INDIVIOR PLC/S has a market capitalization of $1.01 billion and generates $1.01 billion in revenue each year. The company earns $275 million in net income (profit) each year or $1.80 on an earnings per share basis.
What is INDIVIOR PLC/S's official website?
How can I contact INDIVIOR PLC/S?
INDIVIOR PLC/S's mailing address is 103-105 Bath Road, Slough X0, SL1 3UH. The company can be reached via phone at 44-17-5321-7800 or via email at [email protected]
MarketBeat Community Rating for INDIVIOR PLC/S (OTCMKTS INVVY)
MarketBeat's community ratings are surveys of what our community members think about INDIVIOR PLC/S and other stocks. Vote "Outperform" if you believe INVVY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVVY will underperform the S&P 500 over the long term. You may vote once every thirty days.
